Annual Total Long Term Liabilities
$1.27 M
-$1.40 M-52.51%
December 31, 2023
Summary
- As of February 25, 2025, BCLI annual total long term liabilities is $1.27 million, with the most recent change of -$1.40 million (-52.51%) on December 31, 2023.
- During the last 3 years, BCLI annual total long term liabilities has fallen by -$3.30 million (-72.25%).
- BCLI annual total long term liabilities is now -83.57% below its all-time high of $7.70 million, reached on March 1, 2006.
Performance
BCLI Long Term Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Long Term Liabilities
$1.00 M
-$519.00 K-34.17%
September 30, 2024
Summary
- As of February 25, 2025, BCLI quarterly total long term liabilities is $1.00 million, with the most recent change of -$519.00 thousand (-34.17%) on September 30, 2024.
- Over the past year, BCLI quarterly long term liabilities has stayed the same.
- BCLI quarterly long term liabilities is now -87.02% below its all-time high of $7.70 million, reached on March 31, 2006.
Performance
BCLI Quarterly Long Term Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Long Term Liabilities Formula
Long-Term Liabilities = Long-Term Debt + Deferred Tax Liabilities + Pension Liabilities + Other Long-Term Liabilities
BCLI Long Term Liabilities Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -52.5% | 0.0% |
| 3 y3 years | -72.3% | 0.0% |
| 5 y5 years | +100.0% | 0.0% |
BCLI Long Term Liabilities Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -65.0% | at low | -74.6% | at low |
| 5 y | 5-year | -72.3% | +14.8% | -78.1% | +252.1% |
| alltime | all time | -83.6% | -100.0% | -87.0% | -100.0% |
Brainstorm Cell Therapeutics Long Term Liabilities History
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2024 | - | $1.00 M(-34.2%) |
| Jun 2024 | - | $1.52 M(-26.5%) |
| Mar 2024 | - | $2.07 M(+63.3%) |
| Dec 2023 | $1.27 M(-52.5%) | $1.27 M(-34.8%) |
| Sep 2023 | - | $1.94 M(+0.3%) |
| Jun 2023 | - | $1.94 M(-15.4%) |
| Mar 2023 | - | $2.29 M(-14.1%) |
| Dec 2022 | $2.67 M(-26.3%) | $2.67 M(-8.6%) |
| Sep 2022 | - | $2.92 M(-10.6%) |
| Jun 2022 | - | $3.26 M(-17.0%) |
| Mar 2022 | - | $3.93 M(+8.7%) |
| Dec 2021 | $3.62 M(-20.7%) | $3.62 M(-3.9%) |
| Sep 2021 | - | $3.77 M(-5.9%) |
| Jun 2021 | - | $4.00 M(-4.2%) |
| Mar 2021 | - | $4.18 M(-8.4%) |
| Dec 2020 | $4.56 M(+313.6%) | $4.56 M(+1506.3%) |
| Sep 2020 | - | $284.00 K(-49.2%) |
| Jun 2020 | - | $559.00 K(-30.8%) |
| Mar 2020 | - | $808.00 K(-26.7%) |
| Dec 2019 | $1.10 M(>+9900.0%) | $1.10 M(-58.1%) |
| Sep 2019 | - | $2.63 M(-7.3%) |
| Jun 2019 | - | $2.84 M(-6.8%) |
| Mar 2019 | - | $3.04 M(>+9900.0%) |
| Dec 2018 | $0.00(0.0%) | $0.00(0.0%) |
| Sep 2018 | - | $0.00(0.0%) |
| Jun 2018 | - | $0.00(0.0%) |
| Mar 2018 | - | $0.00(0.0%) |
| Dec 2017 | $0.00(0.0%) | $0.00(0.0%) |
| Sep 2017 | - | $0.00(0.0%) |
| Jun 2017 | - | $0.00(0.0%) |
| Mar 2017 | - | $0.00(0.0%) |
| Dec 2016 | $0.00(0.0%) | $0.00(0.0%) |
| Sep 2016 | - | $0.00(0.0%) |
| Jun 2016 | - | $0.00(0.0%) |
| Mar 2016 | - | $0.00(0.0%) |
| Dec 2015 | $0.00(-100.0%) | $0.00(0.0%) |
| Sep 2015 | - | $0.00(0.0%) |
| Jun 2015 | - | $0.00(0.0%) |
| Mar 2015 | - | $0.00(-100.0%) |
| Dec 2014 | $123.00 K | $123.00 K(+18.3%) |
| Sep 2014 | - | $104.00 K(-26.8%) |
| Jun 2014 | - | $142.00 K(-91.8%) |
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2014 | - | $1.73 M(+163.5%) |
| Dec 2013 | $655.00 K(>+9900.0%) | $655.00 K(+125.1%) |
| Sep 2013 | - | $291.00 K(+21.8%) |
| Jun 2013 | - | $239.00 K(+13.8%) |
| Mar 2013 | - | $210.00 K(>+9900.0%) |
| Dec 2012 | $0.00(-100.0%) | $0.00(-100.0%) |
| Sep 2012 | - | $164.00 K(+11.6%) |
| Jun 2012 | - | $147.00 K(+3.5%) |
| Mar 2012 | - | $142.00 K(+17.4%) |
| Dec 2011 | $121.00 K(-3.2%) | $121.00 K(+19.8%) |
| Sep 2011 | - | $101.00 K(+7.4%) |
| Jun 2011 | - | $94.00 K(-26.0%) |
| Mar 2011 | - | $127.00 K(+1.6%) |
| Dec 2010 | $125.00 K(+11.6%) | $125.00 K(+28.9%) |
| Sep 2010 | - | $97.00 K(+18.3%) |
| Jun 2010 | - | $82.00 K(-29.9%) |
| Mar 2010 | - | $117.00 K(+4.5%) |
| Dec 2009 | $112.00 K(+21.7%) | $112.00 K(+10.9%) |
| Sep 2009 | - | $101.00 K(+8.6%) |
| Jun 2009 | - | $93.00 K(+14.8%) |
| Mar 2009 | - | $81.00 K(-12.0%) |
| Dec 2008 | $92.00 K(-67.5%) | $92.00 K(-32.4%) |
| Sep 2008 | - | $136.00 K(-0.7%) |
| Jun 2008 | - | $137.00 K(+37.0%) |
| Mar 2008 | - | $100.00 K(-64.7%) |
| Dec 2007 | $283.00 K(+573.8%) | $283.00 K(-37.1%) |
| Sep 2007 | - | $450.00 K(+733.3%) |
| Jun 2007 | - | $54.00 K(+5.1%) |
| Mar 2007 | - | $51.40 K(+49.0%) |
| Dec 2006 | $42.00 K(-99.5%) | - |
| Sep 2006 | - | $34.50 K(+37.5%) |
| Jun 2006 | - | $25.10 K(-99.7%) |
| Mar 2006 | - | $7.70 M(>+9900.0%) |
| Mar 2006 | $7.70 M(>+9900.0%) | - |
| Dec 2005 | - | $23.70 K(+38.6%) |
| Sep 2005 | - | $17.10 K(+58.3%) |
| Jun 2005 | - | $10.80 K(+83.1%) |
| Mar 2005 | $5900.00(-87.6%) | $5900.00(-87.6%) |
| Mar 2004 | $47.70 K | $47.70 K(+127.1%) |
| Dec 2002 | - | $21.00 K(-34.8%) |
| Sep 2002 | - | $32.20 K(-20.3%) |
| Jun 2002 | - | $40.40 K |
FAQ
- What is Brainstorm Cell Therapeutics annual total long term liabilities?
- What is the all time high annual total long term liabilities for Brainstorm Cell Therapeutics?
- What is Brainstorm Cell Therapeutics annual total long term liabilities year-on-year change?
- What is Brainstorm Cell Therapeutics quarterly total long term liabilities?
- What is the all time high quarterly long term liabilities for Brainstorm Cell Therapeutics?
- What is Brainstorm Cell Therapeutics quarterly long term liabilities year-on-year change?
What is Brainstorm Cell Therapeutics annual total long term liabilities?
The current annual total long term liabilities of BCLI is $1.27 M
What is the all time high annual total long term liabilities for Brainstorm Cell Therapeutics?
Brainstorm Cell Therapeutics all-time high annual total long term liabilities is $7.70 M
What is Brainstorm Cell Therapeutics annual total long term liabilities year-on-year change?
Over the past year, BCLI annual total long term liabilities has changed by -$1.40 M (-52.51%)
What is Brainstorm Cell Therapeutics quarterly total long term liabilities?
The current quarterly long term liabilities of BCLI is $1.00 M
What is the all time high quarterly long term liabilities for Brainstorm Cell Therapeutics?
Brainstorm Cell Therapeutics all-time high quarterly total long term liabilities is $7.70 M
What is Brainstorm Cell Therapeutics quarterly long term liabilities year-on-year change?
Over the past year, BCLI quarterly total long term liabilities has changed by $0.00 (0.00%)